Another similar phase III trial SAFFRON is designed to evaluate the efficacy and safety of the same combined therapy as SACHI versus chemotherapy, but focus on global advanced NSCLC patients with MET amplification/c-MET overexpression that progressed after osimertinib treatment. The gene discussed is MET; the disease is non-small cell lung carcinoma.